Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,417,185
  • Shares Outstanding, K 50,033
  • Annual Sales, $ 249,430 K
  • Annual Income, $ -55,290 K
  • EBIT $ -69 M
  • EBITDA $ -65 M
  • 60-Month Beta 0.73
  • Price/Sales 5.70
  • Price/Cash Flow N/A
  • Price/Book 3.76

Options Overview Details

View History
  • Implied Volatility 73.07% ( -1.31%)
  • Historical Volatility 32.87%
  • IV Percentile 91%
  • IV Rank 44.20%
  • IV High 109.35% on 05/22/24
  • IV Low 44.34% on 02/07/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 2,292
  • Open Int (30-Day) 2,076

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 7
  • High Estimate -0.09
  • Low Estimate -0.93
  • Prior Year -0.40
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.69 +2.29%
on 12/19/24
33.94 -16.55%
on 11/25/24
-4.09 (-12.63%)
since 11/20/24
3-Month
27.69 +2.29%
on 12/19/24
35.47 -20.14%
on 10/28/24
-4.85 (-14.63%)
since 09/20/24
52-Week
27.69 +2.29%
on 12/19/24
76.98 -63.20%
on 02/01/24
-29.97 (-51.41%)
since 12/20/23

Most Recent Stories

More News
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis...

CORT : 51.40 (+0.49%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).He will assume his new role on Dec....

BEAM : 29.01 (+8.04%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen (STK-001), for the treatment of Dravet syndrome, a severe...

IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
STOK : 11.68 (+3.36%)
SPRO : 0.9551 (-4.30%)
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug

Rezolute, Inc. RZLT announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead pipeline candidate, ersodetug (RZ358), for the treatment of hypoglycemia caused by tumor hyperinsulinism...

IMCR : 28.33 (-0.33%)
RZLT : 4.39 (+3.78%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study

Senti Biosciences, Inc. SNTI announced positive initial data from a phase I study that evaluated its chimeric antigen receptor natural killer (CAR-NK) cell therapy candidate, SENTI-202, for the treatment...

IMCR : 28.33 (-0.33%)
SNTI : 3.97 (-0.25%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Immunocore Secures NHS Reimbursement for KIMMTRAK in England for Uveal Melanoma Treatment

Immunocore's KIMMTRAK receives NHS funding for HLA-A*02:01-positive adults with metastatic uveal melanoma after NICE's recent recommendation.Quiver AI SummaryImmunocore has announced that KIMMTRAK (tebentafusp)...

IMCR : 28.33 (-0.33%)
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Esperion Therapeutics, Inc. ESPR announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as a...

ESPR : 2.19 (+0.69%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Altimmune Stock Up More Than 25% in a Month: Here's Why

Altimmune ALT is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis...

IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
ALT : 8.25 (+0.86%)
SPRO : 0.9551 (-4.30%)
Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally...

IMCR : 28.33 (-0.33%)
MIRM : 41.51 (+0.92%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Corcept Shares Rise More Than 60% in Three Months: Here's Why

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s sole-marketed drug, Korlym (mifepristone), which is...

CORT : 51.40 (+0.49%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 30.65
2nd Resistance Point 29.97
1st Resistance Point 29.15
Last Price 28.33
1st Support Level 27.65
2nd Support Level 26.97
3rd Support Level 26.15

See More

52-Week High 76.98
Fibonacci 61.8% 58.15
Fibonacci 50% 52.34
Fibonacci 38.2% 46.52
Last Price 28.33
52-Week Low 27.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar